Results 11 to 20 of about 1,395 (139)

Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma [PDF]

Rheumatology, 2021
AbstractObjectivesTo investigate safety and efficacy of MMF in patients with severe or MTX-refractory juvenile localized scleroderma.MethodsConsecutive juvenile localized scleroderma patients undergoing systemic treatment were included in a retrospective longitudinal study.
Giorgia Martini, Fabio Vittadello, Alessandra Meneghel   +2 more
exaly   +5 more sources

Juvenile localized scleroderma with autoimmune thyroid disorder

Indian Journal of Dermatology, 2010
Hiremath N, Madan Mohan N, Srinivas C, Sangolli Prabhakar, Srinivas K, Vrushali V   +5 more
doaj   +4 more sources

Juvenile Localized Scleroderma. Questions of Treatment

Вопросы современной педиатрии, 2020
Juvenile localized scleroderma (JLS) is a group of childhood diseases with the main symptom — skin and subcutaneous structures lesions, without any organ involvement. There is active (inflammatory) and fibrotic phase in development of JLS.
Rinat K. Raupov, Mikhail M. Kostik
doaj   +9 more sources

Juvenile localized scleroderma: review of 44 patients [PDF]

Pediatric Rheumatology Online Journal, 2011
Predominant form of childhood sclerosis is localized scleroderma (LSc) or morphoea. Preliminary classification includes circumscribed morphoea (CM), linear scleroderma (LS), generalized (GM), panclerotic (PM) and mixed morphoea (MM). The major problem in untreated patients is morbidity, so the aim of the therapy is to prevent this.
Iglesias E, Antón J, Ricart S, Ros J, Torrente V, Bou R, González MA, Vicente A   +7 more
doaj   +4 more sources

Long-term methotrexate efficacy in juvenile localized scleroderma [PDF]

Pediatric Rheumatology Online Journal, 2011
Methods We prospectively followed a cohort of patients with JLS who were enrolled in a double-blind, randomized controlled trial. Oral MTX was used at a dose of 15 mg/m once a week (max 20 mg) for at lest 24 months; prednisone (1 mg/Kg/day, max 50 mg), in a single morning dose for 3 months was added.
Giuliotto S, Zanon G, Vittadello F, Vallongo C, Zulian F, Martini G   +5 more
doaj   +4 more sources

New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review [PDF]

Pharmaceuticals
Background: Juvenile scleroderma (JS) comprises a group of rare chronic autoimmune and fibrosing disorders in children, primarily presenting as juvenile localized scleroderma (jLS) or juvenile systemic sclerosis (jSS). While jLS predominantly affects the
Chiara Sassetti, Claudia Borrelli, Martha Mazuy, Cristina Guerriero, Donato Rigante, Susanna Esposito   +5 more
doaj   +2 more sources

Durometry as an outcome measure in juvenile localized scleroderma. [PDF]

Br J Dermatol, 2016
Poff S, Li SC, Kelsey CE, Foeldvari I, Torok KS.   +4 more
europepmc   +4 more sources

Juvenile eosinophilic fasciitis: a single center case series [PDF]

Pediatric Rheumatology Online Journal
Background Eosinophilic fasciitis (EF) is a rare disease characterized by skin induration and musculoskeletal abnormalities. Diagnostic criteria for EF are based on adult populations.
Leigh A. Stubbs, Oluwaseun Ogunbona, Emily Beil, Vibha Szafron, Adekunle Adesina, Sara Anvari, Jamie Lai, Andrea Ramirez, Matthew G. Ditzler, Marietta DeGuzman   +9 more
doaj   +2 more sources

Reliability of using an ultrasound scoring measure for juvenile localized scleroderma (jLS) [PDF]

Pediatric Rheumatology Online Journal, 2012
Li Suzanne C, Liebling Melissa S, Dempsey-Robertson Molly, Doria Andrea S, Edgerton Stephanie, Hamer Carsten, Jarrin Jose, Kornyat Tanicka, Malone Michael, Mohanta Arun, Opitz Sven, Ramji Faridali, Zhang Shuzhen, Wittkowski Knut   +13 more
doaj   +2 more sources

Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. [PDF]

Arthritis Care Res (Hoboken), 2012
AbstractObjectiveJuvenile localized scleroderma (LS) is a chronic inflammatory skin disorder associated with substantial morbidity and disability. Although a wide range of therapeutic strategies has been reported in the literature, a lack of agreement on treatment specifics and accepted methods for clinical assessment has made it difficult to compare ...
Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Rabinovich CE, Laxer RM, Higgins GC, Ferguson PJ, Lasky A, Baszis K, Becker M, Campillo S, Cartwright V, Cidon M, Inman CJ, Jerath R, O'Neil KM, Vora S, Zeft A, Wallace CA, Ilowite NT, Fuhlbrigge RC, Childhood Arthritis and Rheumatology Research Alliance (CARRA) Localized Scleroderma Workgroup.   +24 more
europepmc   +4 more sources